BioNTech Stock Drops as Sales Outlook Disappoints
1. BioNTech's sales outlook for 2025 is below market expectations. 2. 2025 revenue forecast is 1.7-2.2 billion euros, lower than 2024's 2.8 billion. 3. Q4 EPS was $1.08, exceeding expectations but lower than a year ago. 4. Declining vaccine demand and partner write-downs impact financial outlook. 5. Shares dropped about 3% to $105.28 despite a 9% annual increase.